GlassScriptPhysician profile
Asia Sullivan
NPI 1073074332
$60,907.02
in general payments reported to CMS, 2019-2025
49 companies · $24K in 2025
The $24K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,023 · 2022: $12K · 2023: $5,759 · 2024: $13K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Food and Beverage: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,100 · Travel and Lodging: $3,300 · Long Term Medical Supply Or Device Loan: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,678.05 |
| Food and Beverage | $14,362.67 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,100.00 |
| Travel and Lodging | $3,300.49 |
| Long Term Medical Supply Or Device Loan | $429.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $23,947.90 | 2022-2025 | Arexvy, Shingrix, Bexsero |
| Viiv Healthcare Company | $16,835.52 | 2021-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $8,463.08 | 2021-2025 | Biktarvy, Descovy |
| Eko Health, INC. | $2,108.98 | 2021-2023 | |
| Emd Serono, INC. | $1,150.32 | 2021-2025 | Serostim |
| Biohaven Pharmaceuticals, INC. | $872.54 | 2021 | |
| Merck Sharp & Dohme LLC | $801.45 | 2021-2025 | Pifeltro, Delstrigo, Capvaxive |
| Amgen INC. | $782.13 | 2021-2025 | Repatha, Repatha, Otezla |
| Napo Pharmaceuticals INC | $646.71 | 2022-2025 | Mytesi |
| Janssen Biotech, INC. | $613.05 | 2021-2023 | Symtuza |
| Bausch Health US, LLC | $566.21 | 2021-2025 | Aplenzin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $545.69 | 2021-2025 | Xifaxan, Relistor, Trulance |
| Theratechnologies INC. | $411.82 | 2021-2024 | Trogarzo, Egrifta |
| Abbvie INC. | $363.48 | 2021-2024 | |
| Lilly USA, LLC | $312.18 | 2021-2025 | Zepbound, Mounjaro |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asia Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.